Incanthera PLC
13 July 2026
13 July 2026
Incanthera plc
("Incanthera", the "Company" or "Group")
Corporate Update
Board Changes
Incanthera plc (AQSE: INC) the company focused on innovative technologies in dermatology and oncology, announces that further to the announcement made on 4 June 2026, it has completed the acquisition of the énielle assets ("énielle") and is now working on the integration of the two skin platforms. The Company will promote a single skincare "protect + repair" routine covering both products.
Board Changes
Further to the above, the Company announces the appointment of Ms. Laura Brogden to the Board as Executive Chief Financial Officer and Mr. Werner Bürki as a Non-executive Director. Ms. Brogden has been working with the Company since its spin-out from the University of Bradford in 2010 and the Company believes that Incanthera's immediate and future financial control needs are better met by integrating this critical financial function within the Board.
Mr. Bürki has spent his career working in the banking and finance industry, including 25 years with SIX Group in Switzerland in senior roles including Head of Trading and CEO of the Swiss stock exchange. In this role, Mr. Bürki represented the Swiss Exchange on the Regulatory Board. SIX Group operates the Swiss stock exchange, the Spanish exchanges BME and Aquis in the UK on which the Company is currently listed. Mr. Bürki will now take the lead role in helping the Company manage its corporate governance obligations to stakeholders in order to help drive new value and liquidity.
In addition, the Company announces the appointment of Ms. Caroline Murray as its new Non-executive Chair. Ms. Murray joined the Board in February 2022 as a Non-executive Director and has extensive experience in the pharmaceutical and life sciences industry having held senior positions with global healthcare organisations including Novartis, Bristol-Myers Squibb and Sanofi. A qualified molecular biologist, Ms. Murray combines scientific understanding with commercial leadership and identifies deeply with the Company's mission to bring better skin health to people around the world.
The Company also announces the appointment of Ms. Laura Brogden as Company Secretary with immediate effect. With the appointment of Ms. Brogden as Company Secretary, Ms. Suzanne Brocks has stepped down from this role and as Head of Communications to pursue other business interests. The communications function will in future be provided by external advisers.
The Board would like to thank Ms. Brocks for her dedication in her joint roles as Company Secretary and Head of Communications, and having been with the Company for 11 years, for her invaluable commitment and contribution to the Company. The Board wishes her every success for the future.
The Company's newly constituted Board unanimously agrees that the Company's highest priorities for the immediate future are its new multi-channel sales programmes and minimising the Company's operational costs to ensure cash remains available for future investments and to meet creditor obligations. The Company is now targeting a significant reduction in operational costs driven also by reducing cash compensation by at least 50%. The Board will be compensated mainly, and in most cases, exclusively, through the issue of options over ordinary shares in the Company, subject to regulations, until profitability and shareholder returns are achieved, thereby aligning management compensation with Company performance.
The information to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook has been appended to the end of this announcement.
Stuart Robertson, Chief Executive Officer, said, "This is the first in a series of announcements to come as we reorganise the Company into a far leaner and more focussed sales and stakeholder centric global business. We have been delighted by the enthusiasm and support shown by the Company's partners and stakeholders in helping us deliver on our mission to provide science-led, best-in-class products that improve skin health in a warming world. We have much to do but these first steps have been taken."
This announcement contains inside information for the purposes of the UK Market Abuse Regulation, and the Directors of the Company are responsible for the release of this announcement.
For further information please contact:
|
Incanthera plc Stuart Robertson, Chief Executive Officer stuart.robertson@incanthera.com |
+41 (0) 79 586 5000 |
|
Simon Ward, Chief Scientific Officer simon.ward@incanthera.com |
+44 (0) 7747 625506 |
|
Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner / Liam Murray / Ed Downes
|
+44 (0) 20 7213 0880 |
|
Broker: Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney |
+44 (0) 20 3650 3650/51 |
Notes to Editors
About Incanthera plc
Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.
The Company started as a spin-out from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to identifying commercial partnerships at the earliest opportunity in the development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
About Incanthera's Skincare Portfolio
The Company's skincare offering centres on its flagship brands, Skin+CELL and énielle. These cosmetic products leverage proprietary delivery platforms and advanced formulation techniques to integrate scientifically validated bioactive ingredients into the cosmetic sector. Skin+CELL is positioned as our luxury, clinically-driven skincare brand, merging pharmaceutical enhancement systems with premium cosmetic ingredients to provide high-performance solutions that protect and energise the skin for a radiant appearance. Énielle further expands on this with more natural and organic skincare products, utilising deep scientific foundations to address various consumer needs across multiple categories. All of our products are underpinned by real science and cumulative clinical and customer data.
Developed by experts with significant experience in topical formulations for global pharmaceutical and skincare leading brands, our bioactive technologies focus on reinforcing physiological pathways. These innovative formulations enhance natural repair mechanisms and address critical gaps in skin health. Our skincare portfolio includes dedicated solutions for the face, body, and eyes, including serums and hand care. Looking ahead, the Company continues to innovate with plans for advanced new bioactive SPF products and sophisticated vitamin derivative technologies which combine skincare creams and serums with other skin repair mediums such as hardware and software devices.
Forward looking statement disclaimer
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are statements based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Appendix - AQSE Rule 4.9 Directorship Information
Ms. Laura Jane Brogden, Executive CFO
Ms. Brogden (aged 45) holds the following current or former directorships within the past five years:
|
Current Directorships |
Former Directorships in the past five years |
|
Incanthera Research & Development Ltd |
None |
|
Summ.it Assist LLP |
Ms. Brogden currently holds 405,066 ordinary shares and 2,025,000 options over ordinary shares in the Company.
Mr. Werner Bürki, Non-executive Director
Mr. Bürki (aged 64) holds the following current or former directorships within the past five years:
|
Current Directorships |
Former Directorships in the past five years |
|
None |
12H AG |
|
Edenalp AG |
|
|
RF Nordic Express AB |
|
|
SIX Exfeed AG |
|
|
SIX Repo AG |
|
|
SIX Securities Services AG |
|
|
SIX Swiss Exchange AG |
|
|
SIX Trade Repository AG |
|
|
Swiss Fund Data AG |
Mr. Bürki does not currently hold any shares, or options or warrants over ordinary shares in the Company.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.